ArticleThe New England journal of medicine2016
CDX2 as a Prognostic Biomarker in Colon Cancer.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- CDX2 loss in colorectal cancer cells is associated with invasive properties and tumor budding.Scientific reports · 2025Article
- C1QA is an invariant biomarker for tissue macrophages.bioRxiv : the preprint server for biology · 2024Article
- LIN28B induces a differentiation program through CDX2 in colon cancer.JCI insight · 2021Article
- Boolean implication analysis unveils candidate universal relationships in microbiome data.BMC bioinformatics · 2021Article
- Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer.Frontiers in oncology · 2021Article
- Transcriptional profiling of lung macrophages identifies a predictive signature for inflammatory lung disease in preterm infants.Communications biology · 2020Article
- MNX1 Promotes Malignant Progression of Cervical Cancer via Repressing the Transcription of p21Frontiers in oncology · 2020Article
- Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions.Current oncology (Toronto, Ont.) · 2019Review
- Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.The oncologist · 2019Article
- Identification of gene expression logical invariants inPlant direct · 2019Article
- PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/β-catenin signaling pathway.Cancer cell international · 2019Article
- Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis.Oncotarget · 2017Article
Corrections and comments
- Comment on
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.